| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-09-22 | iOmx Therapeutics (Germany) | € 40 million | series A financing round | Merck Ventures (Germany) MPM Capital (USA - MA) Sofinnova Partners (France) Wellington Partners (UK) | Cancer - Oncology | Series A financing round |
| 2016-09-21 | Artios Pharma (UK) | £25million ($33.2million) | series A financing round | SV Life Sciences (UK - USA) Merck Ventures (Germany) Imperial Innovations (UK) Arix Bioscience (UK) CRT Pioneer Fund (managed by Sixth Element) AbbVie Ventures (USA) | Cancer - Oncology | Series A financing round |
| 2016-09-20 | CxCOG consortium (Theranexus, Synerlab Developpement, Lille University Hospital) (France) | € 3.2 million ($ 3.6 million) | grant | FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France | Neurodegenerative diseases | Grant |
| 2016-09-20 | Agios Pharmaceuticals (USA - MA) | $173 million | private placement | Cancer - Oncology - Rare diseases | Private placement | |
| 2016-09-15 | Eyevensys (France) | € 9 million | series A financing round | Boehringer Ingelheim Venture Fund (Germany), Pontifax Venture Capital (Israel) | Rare diseases - Genetic diseases - Ophtalmological diseases | Series A financing round |
| 2016-09-14 | Theradiag (France) | € 2.5 million | capital increase | HOB Biotech (China) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Diagnostic | Capital increase |
| 2016-09-12 | Angionetics (USA - CA) | $3 million (€2.7 milion) | equity investment | Huapont Life Sciences (China) | Cardiovascular diseases | Fundraising |
| 2016-09-12 | Advantagene (USA - MA) | $14.2 million | series A financing round | National Securities Corporation (USA - NY) | Cancer - Oncology | Series A financing round |
| 2016-09-08 | Avexis (USA - IL) | $127.7 million (€ 113.6 million) | private placement | Rare diseases - Genetic diseases - Neurological diseases | Private placement | |
| 2016-09-01 | OncoDNA (Belgium) | € 7.7 million | financing round | IPG/bio.be (Belgium) Invest4OncoDNA (Belgium) Sambrinvest (Belgium) Vinsovier (Belgium) Sofinim NV (Belgium) SRIW (Belgium) CPH (Belgium) Inventures (USA - CA) | Cancer - Oncology | Financing round |
| 2016-08-30 | Santhera Pharmaceuticals (Switzerland) | $ 246,000 | grant | FDA (USA) | Rare diseases - Genetic diseases - Neuromuscular diseases | Grant |
| 2016-08-23 | OncoMed Pharmaceuticals (USA - CA) | $59.2 million | private placement | Cancer - Oncology | Private placement | |
| 2016-08-12 | Arrowhead Pharmaceuticals (USA - CA) | $45 million | private placement | Orbimed (USa - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) other institutional investors | Private placement | |
| 2016-08-11 | Tapimmune (USA - Fl) | $8.5 million (€7.6 millio) | private placement | Cancer - Oncology | Private placement | |
| 2016-08-10 | Avacta (UK) Leeds University (UK) | £3.8 million (€ 4.4 million) | grant | Medical Research Council (UK) | Infectious diseases - Diagnostic | Grant |
| 2016-08-10 | Epigenomics (Germany - USA) | IPO | Cancer - Oncology - Diagnostic | IPO | ||
| 2016-08-10 | Gemphiire Therapeutics | $30 million | IPO | Liver diseases - Hepatic diseases | IPO | |
| 2016-08-09 | CEL-SCI Corporation (USA -VA) | $5 million | private placement | Cancer - Oncology | Private placement | |
| 2016-08-09 | Y-mAbs Therapeutics (USA - NY) | $ 25 million | seed financing round | Cancer - Oncology | Financing round | |
| 2016-08-09 | Biomarin (USA - CA) | private placement | Private placement |
